EyePoint Pharmaceuticals : Investor Presentation March 2024

Investor Presentation

March 2024

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Legal Disclaimers

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for EYP-1901 in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including EYP-1901 and EYP-2301; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward- looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward- looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

2 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Committed to

developing

therapeutics to

improve the lives of patients with serious retinal diseases

3 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Pipeline represents potential multi billion-dollar opportunities using our bioerodible Durasert E™ IVT delivery technology

• EYP-1901 (vorolanib intravitreal insert) - vorolanib, a selective and patented TKI in Durasert E™
• • Positive topline Phase 2 data in wet AMD
  • First Phase 3 trial in wet AMD planned to initiate in 2H 2024
  • Topline Phase 2 data in NPDR anticipated in Q2 2024
  • Topline Phase 2 data in DME anticipated in Q1 2025
• EYP-2301- razuprotafib, a patented TIE-2 agonist for serious retinal diseases in Durasert E™

Durasert® - proven, safe IVT drug delivery technology

• Bioerodible Durasert E™ and non-erodible formulations
• Safely administered to thousands of patient eyes across four FDA approved products with non-erodible formulations

Strong Balance Sheet

• $331M of cash and investments on December 31, 2023
• Cash runway through Phase 3 wet AMD pivotal trials topline data in 2026

IVT, intravitreal injection

Pipeline Represents Potential Multi Billion-Dollar Product Opportunities

Durasert E™ Programs	Indication	Discovery	Pre-Clin	Phase 1	Phase 2	Phase 3	Next Milestone
	Wet AMD	single-dose,6-month maintenance therapy		EOP2 Mtg with FDA
		Q2 2024
EYP-1901 - vorolanib in
Durasert E™	NPDR	single-dose,9-month treatment			Topline data in
(tyrosine kinase inhibitor)			Q2 2024
	DME	single-dose,6-month treatment			Topline data in
			Q1 2025
EYP-2301 - razuprotafib in	serious retinal						Pre-clin tox and PK
Durasert E™
diseases						data
(TIE-2 agonist)
Complement inhibition	GA						Potential product
					candidate in 2024

	non-clinical	trial planned	trial underway
4	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	wet AMD, wet age-related macular degeneration; EOP2, End of Phase 2; FPI, first patient in; NPDR,
non-proliferative diabetic retinopathy; DME, diabetic macular edema; GA, geographic atrophy

Durasert - Intravitreal Sustained-Release Drug Delivery

	Safe, Sustained IVT Drug Delivery
TECHNOLOGY	• Delivered via a standard in-office IVT injection
DURASERT®	• Continuous, stable release of drug

• Zero-order kinetics

Durasert E™: bioerodible

• Insert consists of drug embedded within a bioerodible matrix
• Designed to deplete drug load before matrix fully erodes

Durasert®: non-erodible

• Drug embedded within a bioerodible matrix covered with non- erodible polyimide shell:
• • YUTIQ®1
  • ILUVIEN®1
  • RETISERT®2
  • VITRASERT®2

5	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	1- licensed to Alimera; 2 - licensed to Bausch and Lomb

Vorolanib Brings a Potential New MOA to the Treatment of VEGF- Mediated Retinal Diseases by Inhibiting all Isoforms of VEGF and PDGF

• Potent and selective pan-VEGF receptor inhibition
• Composition of matter patent into 2037
• Demonstrated neuroprotection in a validated retinal detachment animal model
• Inhibits PDGF which may lead to antifibrotic benefit
• Reduced off-target binding - does not inhibit TIE-2 at clinically relevant doses

		SoC, standard of care; ANG, angiopoietin; PDGF(R), platelet-derived growth factor
6	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	(receptor); PLGF, placental growth factor; TIE-2,tyrosine-protein kinase receptor
		TIE-2; VEGF(R), vascular endothelial growth factor (receptor).

EYP-1901: VEGF Receptor Binding Vorolanib In Bioerodible Durasert E™

Insert is ~1/5000 of vitreous volume

7 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

• Positive efficacy data in wet AMD from Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials
• Favorable safety profile with no ocular or systemic EYP-1901-related SAEs reported in ongoing Phase 2 clinical trials
• Immediately bioavailable featuring an initial burst of drug followed by zero order kinetics release for ~9 months
• Vorolanib fully eluted prior to complete bioerosion of the matrix to control release and allow redosing regimen
• Delivered in the physician office via routine intravitreal injection
• Shipped and stored at ambient temperature

VEGF - vascular endothelial growth factor: AMD - age related macular degeneration;

Phase 2 DAVIO 2 Clinical Trial Topline Results in wet AMD

1. NON-INFERIORITYTRIAL VERSUS AN AFLIBERCEPT CONTROL

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

The DAVIO 2

Clinical Trial in wet

AMD

1. non-inferioritytrial evaluating two
   doses of EYP-
   1901 against an aflibercept control as a 6-month maintenance

therapy

9 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Design:

Multi-center, randomized, double-masked trial in patients with previously treated wet

AMD

Primary outcome:

Difference in mean change in BCVA from Day 1 to Week 28 and 32 (blended)

Key secondary endpoints:

• Safety
• Reduction in treatment burden
• Percent of eyes supplement-free up to six months Anatomical results

Anti-VEGF supplement criteria:

• 5 letter loss with 75 microns of new fluid
• 10 letter loss due to wet AMD
• 100 microns new fluid x 2 visits
• New retinal hemorrhage from wet AMD
• Investigator discretion

DAVIO 2 Clinical Trial is Randomized, Double-Masked, Aflibercept Controlled* with a Single EYP-1901 Treatment at Two Doses

-D14 to -D7 D1

W 4

W 8

W 12

W 16

W 20

W 24

W 28

W 32 W 36 to W 56

EYP-1901 2mg low dose n=53

EYP-1901 3mg high dose n=54

Aflibercept 2mg q8W n=54

R A N D O M I Z A T I O N

	A F L I B E R C E P T q 8 W
E Y P - 1 9 0 1 / A F L I B E R C E P T	1 ⁰ E N D P O I N T B L E N D W 2 8
A ND W 3 2 ; UNMA S K W 3 2

REQUIRED AFLIBERCEPT	VISIT	EYP-1901 DOSE	SHAM INJECTION FOR MASKING
INJECTION VISIT	SCHEDULED
10 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	*Aflibercept on-label control required by FDA